Description
Anti-ACVR2B Antibody, Highly Galactosylated (BioBet-GA-060ZP) is a human IgG1, λ antibody against ACVR2B which contains with a high level of galactosylation.
Antibody Indication
Cachexia
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ACVR2B antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ACVR2B
Full Name
Activin A Receptor Type 2B
Background
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008]
Alternative Names
Bimagrumab; 1356922-05-8; BYM338; BYM338; ACVR2B; activin A receptor, type IIB; activin receptor type-2B; ActR IIB; HTX4; ACTRIIB; ActR-IIB;
Gene ID
93
UniProt ID
Q13705
Cellular Localization
Plasma membrane
Genecards
174
Involvement in Disease
Its related pathways are Signaling by NODAL and Signaling by GPCR.
Related Pathways
The transmembrane serine/threonine kinase activator protein type 2 receptor and the activin type 1 serine/threonine kinase receptor (ACVR1, ACVR1B or ACVR1c) form an activator protein receptor complex. It can sense activin signals from the cell surface to the cytoplasm, thus regulating many physiological and pathological processes including neuron differentiation and neuron survival, hair follicle development and circulation, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression And carcinogenic effects. Activin is also believed to have a paracrine or autocrine effect in the development of ovarian follicles. In the receptor complex, type 2 receptors are the main activin receptors (binding activin-a /INHBA, activin-b /INHBB and inhibitory protein-a /INHA-INHBA). Type 1 receptors such as ACVR1B act as downstream transducers of activin signals. The activator protein binds to the type 2 receptor on the plasma membrane and activates its serine-threonine kinase. The activated type 2 receptor then phosphorylates and activates the type 1 receptor. Once activated, type 1 receptors bind to and phosphorylate the SMAD proteins SMAD2 and SMAD3 at the c-terminal serine residue. Shortly after SMAD2 and SMAD3 bind to the activin receptor and are subsequently phosphorylated, they are released into the cytoplasm and interact with their common partner SMAD4. This SMAD complex is transferred to the nucleus, where it mediates activity-induced transcription. Inhibition of SMAD7 being recruited to ACVR1B through FKBP1A can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking activin signaling. Activin signal transduction is also antagonized by the binding of the IGSF1 inhibin co-receptor to the inhibin-b receptor.
Field of research
1.Phosphorylated. Constitutive phosphorylation is in part catalyzed by its own kinase activity. 2.Glycosylation at Asn42 and Asn65 3.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, λ
Antibody Clone
BioBet-GA-060ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human ACVR2B. Bimagrumab is a human monoclonal antibody developed to treat pathological muscle loss and weakness.
Antibody Indication
Cachexia
